ArticleBMC bioinformatics2025
Integrating genetic and gene expression data in network-based stratification analysis of cancers.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundCancers are complex diseases that have heterogeneous genetic drivers and varying clinical outcomes. A critical area of cancer research is organizing patient cohorts into subtypes and associating subtypes with clinical and biological outcomes for more effective prognosis and treatment. Large-scale studies have collected a plethora of omics data across multiple tumor types, providing an extensive dataset for stratifying patient cohorts. Network-based stratification (NBS) approaches have been presented to classify cancer tumors using somatic mutation data. A challenge in cancer stratification is integrating omics data to yield clinically meaningful subtypes. In this study, we investigate a novel approach to the NBS framework by integrating somatic mutation data with RNA sequencing data and investigating the effectiveness of integrated NBS on three cancers: ovarian, bladder, and uterine cancer.
resultsWe show that integrated NBS subtypes are more significantly associated with overall survival or histology. Specifically, we observe that integrated NBS subtypes for ovarian and bladder cancer were more significantly associated with patient survival than single-data type NBS subtypes, even when accounting for covariates. In addition, we show that integrated NBS subtypes for bladder and uterine are more significantly associated with tumor histology than single-data type NBS subtypes. Integrated NBS networks also reveal highly influential genes that span across multiple integrated NBS subtypes and subtype-specific genes. Pathway enrichment analysis of integrated NBS subtypes reveal overarching biological differences between subtypes. These genes and pathways are involved in a heterogeneous set of cell functions, including ubiquitin homeostasis, p53 regulation, cytokine and chemokine signaling, and cell proliferation, emphasizing the importance of identifying not only cancer-specific gene drivers but also subtype-specific tumor drivers.
conclusionsOur study highlights the significance of integrating multi-omics data within the NBS framework to enhance cancer subtyping, specifically its utility in offering profound implications for personalized prognosis and treatment strategies. These insights contribute to the ongoing advancement of computational subtyping methods to uncover more targeted and effective therapeutic treatments while facilitating the discovery of cancer driver genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.